Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « X. Lataste »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
X. Ferrer < X. Lataste < XIAOJUN LIU  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 3.
Ident.Authors (with country if any)Title
000654 (1992) Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse]Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
000660 (1992) M. Emre [Suisse] ; U. K. Rinne ; A. Rascol ; A. Lees ; Yves Agid [France] ; X. LatasteEffects of a selective partial D1 agonist, CY 208-243, in De Novo patients with Parkinson disease
000672 (1989) J. A. Temlett [Suisse] ; N. P. Quinn [Royaume-Uni] ; P. G. Jenner [Suisse] ; C. D. Marsden [Royaume-Uni] ; E. Pourcher [France] ; A. Bonnet [France] ; Yves Agid [France] ; R. Markstein [Suisse] ; X. Lataste [Suisse]Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's disease

List of associated KwdEn.i

Nombre de
documents
Descripteur
3Parkinson disease
2Aged
2Antiparkinson agent
2Chemotherapy
2D1 Dopamine receptor
2Dopamine agonist
2Female
2Human
2Humans
2Indoles (therapeutic use)
2Male
2Middle Aged
2Parkinson Disease (drug therapy)
2Phenanthridines (therapeutic use)
2Treatment
11-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1Adult
1Analgesics (therapeutic use)
1Animal
1Animals
1Antiparkinson Agents (therapeutic use)
1Bromocriptine (therapeutic use)
1CY 208–243
1Callitrichinae
1D1‐receptor agonists
1Dopamine Agents (therapeutic use)
1Dopamine agonists
1Dose activity relation
1Dose-Response Relationship, Drug
1Drug Administration Schedule
1Drug Therapy, Combination
1D‐1 Agonist Drugs
1Experimental disease
1Involuntary movement
1Levodopa (therapeutic use)
1Monkey
1Nervous system diseases
1Neurologic Examination (drug effects)
1Parkinson Disease (physiopathology)
1Parkinson Disease, Secondary (chemically induced)
1Parkinson's Disease
1Pyridines
1Receptors, Dopamine (drug effects)
1Receptors, Dopamine (physiology)
1Receptors, Dopamine D1
1Subcutaneous administration
1Tolerance

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "X. Lataste" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "X. Lataste" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    X. Lataste
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024